Catumaxomab, now branded as
Korjuny
○
Search Drug
, received a positive opinion from the
EMA
○
Search Organization
's
CHMP
○
Search Organization
for treating malignant ascites, marking its return after a decade off the market.
Korjuny
○
Search Drug
, a bispecific and trifunctional antibody, engages Epcam on cancer cells and CD3 on T cells, recruiting immune cells to destroy tumor cells. The
EMA
○
Search Organization
approval is limited to malignant ascites, but ongoing trials aim to expand its use, including a global phase III trial in advanced gastric cancer.